PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.080
-0.110 (-9.24%)
Apr 1, 2025, 4:00 PM EDT - Market closed
PDS Biotechnology Employees
PDS Biotechnology had 25 employees as of December 31, 2023. The number of employees decreased by 1 or -3.85% compared to the previous year.
Employees
25
Change (1Y)
-1
Growth (1Y)
-3.85%
Revenue / Employee
n/a
Profits / Employee
-$1,504,415
Market Cap
40.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 5 days ago - PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 7 days ago - PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - GlobeNewsWire
- 14 days ago - PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - GlobeNewsWire
- 19 days ago - PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - GlobeNewsWire
- 21 days ago - PDS Biotech Leadership to Participate in March Conferences - GlobeNewsWire
- 25 days ago - PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - GlobeNewsWire
- 4 weeks ago - PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire